At 5.4% CAGR, Middle East & Africa Cough Drops Market is Projected to be Worth US$ 136.27 Million by 2031, says Business Market Insights

According to Business Market Insights research, the Middle East & Africa cough drops market was valued at US$ 89.26 million in 2023 and is expected to reach US$ 136.27 million by 2031, registering a CAGR of 5.4% from 2023 to 2031. The rising burden of respiratory diseases causing sore throat and increasing shift toward self-medication are among the critical factors attributed to driving the Middle East & Africa cough drops market growth.

Viral infections such as colds or influenza are among the common causes of sore throat. A sore throat can also indicate strep throat, the common cold, allergies, or other upper respiratory illnesses. According to the World Health Organization, approximately 1 billion cases of seasonal influenza are recorded every year across the globe, including 3–5 million cases of severe illness. Symptoms typically start 1–4 days after infection and persist for about a week. The common cold, flu, and seasonal allergies are widespread respiratory issues that significantly increase the demand for cough relief products as people seek immediate relief from coughing, throat irritation, and other symptoms causing discomfort. Deteriorating air quality due to rapid-paced urbanization has been a significant concern for health systems across the world, contributing to a rise in cases of respiratory illnesses. Pollutants can worsen the health conditions of asthma and bronchitis patients, leading to more frequent coughing episodes. Consequently, consumers are increasingly seeking cough drops for relief from these symptoms.

The geriatric population is particularly vulnerable to respiratory disorders due to decreased immunity and pre-existing health conditions. The world's population is aging at an unparalleled rate. According to the WHO facts published in October 2022, 1 in 6 individuals worldwide would be aged 60 or more by 2030. Thus, the number of people from this age group would increase from 1 billion in 2020 to 1.4 billion by 2030; the population would rise by quadruple to 2.1 billion by 2050. Furthermore, it is anticipated that the population of those aged 80 or older will triple between 2020 and 2050, reaching 426 million. As people age, they are more likely to experience chronic illnesses that require symptom management, including the use of cough drops for relief from coughing associated with infections or chronic conditions. According to an article published in Annals of Research Hospitals in 2018, the rising prevalence of chronic lung diseases and iatrogenic immunosuppression are leading to an increase in respiratory infections in an aging population. Moreover, 2 billion people worldwide will be older than 65 years, and more than 1 billion individuals will have a preventable chronic lung disease by 2050. In response to the rising incidence of respiratory disorders, manufacturers in the cough drops market are innovating their product lines and adopting development strategies such as collaborations and partnerships to expand their businesses. Thus, the rising burden of respiratory diseases causing sore throat fuels the growth of the cough drops market across the world.

On the contrary, the inability to provide long-term relief and availability of alternatives hampers the growth of Middle East & Africa cough drops market.

By product, the Middle East & Africa cough drops market is segmented into gluten free, sugar free, and others. The sugar free held 49.0% share of Middle East & Africa cough drops market share in 2023, amassing US$ 43.75 million. It is projected to garner US$ 68.32 million by 2031 to register 5.7% CAGR during 2023–2031.

By application, the Middle East & Africa cough drops market is bifurcated into adults and children. The adults held 83.9% share of Middle East & Africa cough drops market share in 2023, amassing US$ 74.88 million. It is projected to garner US$ 115.81 million by 2031 to register 5.6% CAGR during 2023–2031.

By distribution channel the Middle East & Africa cough drops market is bifurcated into offline and online. The offline held 71.3% share of Middle East & Africa cough drops market share in 2023, amassing US$ 63.66 million. It is projected to garner US$ 94.84 million by 2031 to register 5.1% CAGR during 2023–2031.

Based on country, the Middle East & Africa cough drops market is categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that South Africa captured 36.5% share of Middle East & Africa cough drops market in 2023. It was assessed at US$ 32.59 million in 2023 and is likely to hit US$ 50.89 million by 2031, registering a CAGR of 5.7% during 2023–2031.

Key players operating in the cough drops market are Bliss GVS Pharma Ltd, Cipla Ltd, Gepach International, GSK Plc, Mondelez International Inc, Reckitt Benckiser Group Plc, Ricola, Sanofi SA, The Procter & Gamble Co, and Thornton & Ross, among others.

• In September 2024: Cofsils, a brand by Cipla Health Ltd. specializing in sore throat relief, launched a new flavor: Cofsils Mulethi. This lozenge offers the soothing taste of Mulethi (Licorice) and provides relief from sore throat in just five minutes. Cofsils Mulethi joined the existing flavors, including Cofsils Fresh Mint, Cofsils Tulsi Pudina, and popular options like Cofsils Orange, Lemon Honey, and Ginger Lemon.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com